In many cancer patients who have been treated with immunotherapy, the tumor comes back. New research identifies the cells responsible for thwarting the treatment and offers new insights into how they do it.
Recent research has shown that a drug known as MI-2 can kill cells that cause a fatal brain cancer. But only now have scientists been able to explain how the compound works: by targeting cholesterol production in tumors.
Some cancers have been traced to changes in histones, proteins responsible for packaging DNA and regulating genes. Now, research from Rockefeller scientists shows that, among tumors, mutations to these proteins are a lot more common than previously suspected.
Scientists discovered a protein that plays a crucial role in regulating fatty acids, the molecules that make up body fat. This research could lead to new options for treating people with diseases associated with fatty acid buildup.
Researchers have identified a rare type of cancer cell that cannot make cholesterol, a key nutrient. By targeting this deficiency, scientists may be able to develop new strategies for treating the disease.